{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:13:51Z","timestamp":1788394431893,"version":"build-2803163510"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To report the reasons for treatment discontinuation within 5 years in patients receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for neovascular age-related macular degeneration (nAMD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective case-notes review of patients commenced on anti-VEGF for nAMD who failed to complete 5 years of follow-up was undertaken. The reasons for treatment discontinuation, baseline age, baseline visual acuity (VA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letters, and the VA change at the last follow-up were recorded. Age-specific all-cause mortality was calculated for deceased patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of the 1177 patients, 551 patients (46.8%) failed to complete the 5-year follow-up. The reasons for treatment discontinuation were death (251), early discharge due to stable disease (110), further treatment deemed futile (100), failure to attend (15), ill health (14), patient choice (7), and transfer of care (1). In 53 patients, no reason was documented. The mean baseline age of those who completed the 5-year follow-up (77.4 \u00b1 7.8 years, 95% confidence interval (CI): 76.8\u201377.9) was significantly lower than those who discontinued the treatment for any reason (82 \u00b1 7.7 years, 95% CI: 81.4\u201382.6) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001). Survival analysis showed that baseline VA was not a factor in treatment discontinuation; however, visual stability (\u00b15 letters from baseline) was associated with treatment continuation. The age-specific all-cause mortality in deceased patients was lower than that in the general population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>At 5 years, only 53% of patients remained in active care, and death was the most common reason for treatment discontinuation. Lower baseline age and VA stability during therapy were associated with treatment continuation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_3066_21","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T07:18:21Z","timestamp":1654067901000},"page":"2065-2070","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Patterns of treatment discontinuation in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration"],"prefix":"10.4103","volume":"70","author":[{"given":"Narendra","family":"Dhingra","sequence":"first","affiliation":[{"name":"Macula Service, Eye Centre, Mid Yorkshire NHS Trust, Wakefield, WF1 2DG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Upasani","sequence":"additional","affiliation":[{"name":"Macula Service, Eye Centre, Mid Yorkshire NHS Trust, Wakefield, WF1 2DG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faruque D","family":"Ghanchi","sequence":"additional","affiliation":[{"name":"Bradford Teaching Hospitals, NHS Foundation Trust, Duckworth Lane, Bradford, BD9 6RJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"R1-20251004","first-page":"e144","article-title":"GBD 2019 Blindness and Vision Impairment Collaborators;Vision Loss Expert Group of the Global Burden of Disease Study, Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020:The right to sight:An analysis for the Global Burden of disease study","volume":"9","year":"2021","journal-title":"Lancet Glob Health"},{"key":"R2-20251004","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040:A systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"R3-20251004","doi-asserted-by":"crossref","first-page":"e101072","DOI":"10.1371\/journal.pone.0101072","article-title":"Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment","volume":"9","author":"Mitchell","year":"2014","journal-title":"PLoS One"},{"key":"R4-20251004","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration:Two-year results of the ANCHOR study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"key":"R5-20251004","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"R6-20251004","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"R7-20251004","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON:A multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"R8-20251004","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.ophtha.2020.03.020","article-title":"IVAN Study Group. Long-term visual outcomes after release from protocol in patients who participated in the Inhibition of VEGF in age-related choroidal neovascularisation (IVAN) trial","volume":"127","author":"Evans","year":"2020","journal-title":"Ophthalmology"},{"key":"R9-20251004","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration:A mixed-methods systematic review","volume":"128","author":"Okada","year":"2021","journal-title":"Ophthalmology"},{"key":"R10-20251004","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2019.10.007","article-title":"Ten-year treatment outcomes of neovascular age-related macular degeneration from two regions","volume":"210","author":"Gillies","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"R11-20251004","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/s41433-020-0764-9","article-title":"Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration","volume":"34","author":"Chandra","year":"2020","journal-title":"Eye (Lond)"},{"key":"R12-20251004","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/ceo.13742","article-title":"Ten-year outcomes of anti-vascular endothelial growth factor treatment for neovascular age-related macular disease:A single-centre French study","volume":"48","author":"Wolff","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"key":"R13-20251004","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2147\/OPTH.S90913","article-title":"Treatment of neovascular age-related macular degeneration with anti-VEGF agents:Retrospective analysis of 5-year outcomes","volume":"10","author":"Pedrosa","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"R14-20251004","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1136\/bjophthalmol-2017-311055","article-title":"Outcome of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in real-life setting","volume":"102","author":"Kataja","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"R15-20251004","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fmed.2018.00125","article-title":"Outcome of 5-year treatment of neovascular age-related macular degeneration with intravitreal anti-VEGF using \u201cTreat and Extend\u201cregimen","volume":"5","author":"Jaki Mekjavic","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"R16-20251004","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2147\/OPTH.S101050","article-title":"Ranibizumab in neovascular age-related macular degeneration:A 5-year follow-up","volume":"10","author":"Cvetkova","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"R17-20251004","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41433-020-0851-y","article-title":"Impact of injection frequency on 5-year real-world visual acuity outcomes of aflibercept therapy for neovascular age-related macular degeneration","volume":"35","author":"Chandra","year":"2021","journal-title":"Eye (Lond)"},{"key":"R18-20251004","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1097\/IAE.0000000000000173","article-title":"Reasons for discontinuation of intravitreal vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration","volume":"34","author":"Vaze","year":"2014","journal-title":"Retina"},{"key":"R19-20251004","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ajo.2012.06.031","article-title":"Four year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment","volume":"155","author":"Kruger Falk","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R20-20251004","doi-asserted-by":"crossref","first-page":"777","DOI":"10.5301\/EJO.2011.7430","article-title":"Remission and dropout rate of anti-VEGF therapy for age-related macular degeneration","volume":"21","author":"Oishi","year":"2011","journal-title":"Eur J Ophthalmol"},{"key":"R21-20251004","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jamaophthalmol.2018.3578","article-title":"Loss to follow-up among patients with neovascular age-related macular degeneration who received intravitreal anti-vascular endothelial growth factor injections","volume":"136","author":"Obeid","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R23-20251004","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.oret.2019.07.010","article-title":"Outcomes of Eyes lost to follow-up with neovascular age-related macular degeneration receiving intravitreal anti-vascular endothelial growth factor","volume":"4","author":"Soares","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"12","key":"R24-20251004","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/eye.2013.233","article-title":"AMD Guidelines Group (2013). The Royal College of Ophthalmologists Guidelines on AMD:Executive Summary","volume":"27","author":"Chakravarthy","journal-title":"Eye (London, England)"},{"key":"R25-20251004","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/eye.2015.48","article-title":"Defining response to anti-VEGF therapies in neovascular AMD","volume":"29","author":"Amoaku","year":"2015","journal-title":"Eye (Lond)"},{"key":"R26-20251004","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000451065","article-title":"Characteristics and predictors of early and delayed responders to ranibizumab treatment in neovascular age-related macular degeneration:A retrospective analysis from the ANCHOR, MARINA, HARBOR, and CATT trials","volume":"236","author":"Gale","year":"2016","journal-title":"Ophthalmologica"},{"key":"R27-20251004","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.2147\/OPTH.S275977","article-title":"Trends in real-world neovascular AMD treatment outcomes in the UK","volume":"14","author":"Mehta","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"R28-20251004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000502747","article-title":"Undertreatment of neovascular age-related macular degeneration after 10 years of anti-vascular endothelial growth factor therapy in the real world:The need for a change of mindset","volume":"243","author":"Mon\u00e9s","year":"2020","journal-title":"Ophthalmologica"},{"key":"R29-20251004","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","article-title":"Fight Retinal Blindness Study Group. Long-term outcomes of treatment of neovascular age-related macular degeneration:Data from an observational study","volume":"122","author":"Gillies","year":"2015","journal-title":"Ophthalmology"},{"key":"R30-20251004","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/IAE.0000000000002713","article-title":"on behalf of the Vision Academy Steering Committee, Suspending treatment of neovascular age-related macular degeneration in cases of futility","volume":"40","author":"Wong","year":"2020","journal-title":"Retina"},{"key":"R31-20251004","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.ophtha.2016.06.053","article-title":"Introduction of anti-VEGF therapies for age-related macular degeneration did not raise risk of myocardial infarction, stroke, and death","volume":"123","author":"Yashkin","year":"2016","journal-title":"Ophthalmology"},{"key":"R32-20251004","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jamaophthalmol.2018.6891","article-title":"Association of intravitreal anti-vascular endothelial growth factor therapy with risk of stroke, myocardial infarction, and death in patients with exudative age-related macular degeneration","volume":"137","author":"Dalvin","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"R33-20251004","doi-asserted-by":"crossref","first-page":"7194927","DOI":"10.1155\/2017\/7194927","article-title":"Neovascular age-related macular degeneration in the very old (\u226590 years):Epidemiology, adherence to treatment, and comparison of efficacy","volume":"2017","author":"Subhi","year":"2017","journal-title":"J Ophthalmol"},{"key":"R34-20251004","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.4103\/ijo.IJO_1866_19","article-title":"Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema","volume":"68","author":"Kelkar","year":"2020","journal-title":"Indian J Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_3066_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:51:58Z","timestamp":1786647118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_3066_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_3066_21","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]},"assertion":[{"value":"2021-12-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}